Tag
This review synthesizes evidence on dual antiglutamate therapy combining AMPA and NMDA receptor blockade in postanoxic super-refractory status epilepticus, highlighting the SUPER-CAT study’s demonstration of improved seizure resolutio
A recent randomized clinical trial reveals that adjunctive intravenous ketamine significantly reduces depressive symptoms in treatment-resistant bipolar depression, with good safety and tolerability compared to midazolam.
This randomized clinical trial demonstrates no clinically meaningful difference in pain relief between 20 mg intranasal and subcutaneous ketamine for acute musculoskeletal trauma in the emergency department, with minor adverse events being
A randomized controlled trial demonstrates that adjunct low-dose ketamine infusion safely decreases opioid use in mechanically ventilated adults without increasing delirium or adverse events, suggesting potential benefits in ICU analgosedat
This study reveals that general anesthesia selectively modulates ketamine-induced EEG changes, preserving beta-gamma oscillations while attenuating theta augmentation, highlighting discrete neurophysiologic components underlying ketamine
This article explores recent evidence comparing ketamine and etomidate for rapid sequence intubation. While new cohort data suggests a mortality benefit for ketamine, meta-analyses of randomized trials show clinical equipoise, highlighting
The large-scale RSI randomized trial found no significant difference in 28-day mortality between ketamine and etomidate for intubating critically ill adults, though ketamine was associated with a higher risk of cardiovascular collapse.
The KARMA-Dep 2 trial reveals that serial ketamine infusions do not significantly outperform midazolam in reducing depressive symptoms among inpatients receiving usual psychiatric care, challenging assumptions about ketamine’s long-term ant
